Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Receivables (2022 - 2025)

Historic Receivables for BioXcel Therapeutics (BTAI) over the last 4 years, with Q2 2025 value amounting to $17000.0.

  • BioXcel Therapeutics' Receivables fell 9790.64% to $17000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $17000.0, marking a year-over-year decrease of 9790.64%. This contributed to the annual value of $131000.0 for FY2024, which is 8450.7% up from last year.
  • According to the latest figures from Q2 2025, BioXcel Therapeutics' Receivables is $17000.0, which was down 9790.64% from $131000.0 recorded in Q4 2024.
  • BioXcel Therapeutics' 5-year Receivables high stood at $812000.0 for Q2 2024, and its period low was $3000.0 during Q3 2024.
  • Moreover, its 4-year median value for Receivables was $265500.0 (2022), whereas its average is $310900.0.
  • Examining YoY changes over the last 5 years, BioXcel Therapeutics' Receivables showed a top increase of 8839.91% in 2024 and a maximum decrease of 9959.18% in 2024.
  • Over the past 4 years, BioXcel Therapeutics' Receivables (Quarter) stood at $248000.0 in 2022, then plummeted by 71.37% to $71000.0 in 2023, then skyrocketed by 84.51% to $131000.0 in 2024, then plummeted by 87.02% to $17000.0 in 2025.
  • Its Receivables was $17000.0 in Q2 2025, compared to $131000.0 in Q4 2024 and $3000.0 in Q3 2024.